NuVision® Biotherapies Limited is a regenerative medicine company spun out the University of Nottingham in 2015. Dr Andrew Hopkinson founded NuVision on investment from Mercia Fund Management to develop and accelerate to market cutting edge and disruptive regenerative therapies. The MediCity-based manufacturing company produces a ground-breaking high-quality and affordable platform technology, initially focusing on treating front of the eye disease and trauma, but now expanding into the chronic wound arena over the next year.
Omnigen ® is a unique ‘off the shelf’, transportable biological matrix that can be used as an effective wound dressing for a range of indications including ocular surface indications. Omnigen will equip those civilian, military and veterinary surgeons tasked with treating damaged corneas with an immediately accessible, consistent high quality, and reliable product.
Since its founding in 2016, NuVision Boitherapies has raised over $3m from investors including University of NOttingham, Biocity, Mercia and MEIF.